Savings Insurance
Grow and protect your wealth
Critical Illness Protection · Life Protection · Savings
Period
Issue age of Insured
You can buy this from
Life can be full of relentless challenges when it comes to your wellbeing, so it’s essential to plan ahead.
AIA is committed to extending cover to give protection to more people, which is why we are the first in the market to expand our protection to individuals with benign conditions that could potentially increase the risk of cancer. To meet the full range of your critical illness needs, we also provide you multiple cover as high as 900% of the amount you purchased.
As an integrated plan created to offer you multiple illnesses protection, life insurance protection and potential long term savings, the brand new Smart Elite Ultra takes care of different critical illness needs from prevention to protection, and rehabilitation, we stand by you to overcome every hurdle in life.
Limited time offerApply now to enjoy 1% premium refund. |
Terms & conditions apply. Details please download and refer to the promotion leaflet.
Smart Elite Ultra is a participating insurance plan that provides you with life insurance and multiple illnesses protection in lump sum payment. This plan can be purchased as a basic plan, giving you comprehensive cover for 58 critical illnesses (including 57 major illnesses and 1 minor illness), 44 early stage critical illnesses (including minimally invasive surgery and treatment and Carcinoma-in-situ and early stage cancer), 13 severe child diseases as well as the opportunity to enhance your savings, supporting you through all the different stages of your life.
If the insured, who is the person protected under the policy, passes away, we will pay the death benefit to the person whom you select in your policy as the beneficiary. The death benefit will include:
In addition, we will pay a compassionate cash benefit equal to 5% of the Initial Sum Assured regardless of whether any claims payments have been made previously.
Current Sum Assured means the sum assured left after deduction of all advance payment(s) made for the benefits for a major illness, minor illness, early stage critical illness, diabetes complication and / or severe child disease from the Initial Sum Assured. The Initial Sum Assured means the protection amount that you have purchased.
We will deduct all outstanding debt under your policy before making any claim payment.
Though modern medical advancements have raised the average life expectancy, greater longevity comes with an increased risk of multiple illnesses. And with each subsequent occurrence of critical illness, health deteriorates and the severity of symptoms and complications increases dramatically, which is why we provide the multiple illnesses protection that includes up to 3 times cover for cancer and up to 2 times cover for heart attack, giving you and your family lasting peace of mind.
Smart Elite Ultra provides cover for 115 illnesses, which are divided into 6 groups. The maximum benefit of each Critical Illness Group is as follows:
Critical Illness Group: Maximum Benefit (% of Initial Sum Assured)
Group 1 – Cancer: 300%
Group 2 – Illnesses related to the Heart: 200%
Group 3 – Illnesses related to the Nervous System: 100%
Group 4 – Illnesses related to Major Organs and Functions: 100%
Group 5 – Other Major Illnesses: 100%
Group 6 – Terminal Illness and Loss of Independent Existence: 100%▲
▲ Terminal Illness and Loss of Independent Existence claims are only payable if (a) the insured’s condition does not meet the definition of any other covered critical illnesses in Critical Illness Groups 1, 2, 3, 4 and 5, and (b) no claim for major illness has been made before. Once the insured has made the first claim for major illness, the benefit under Critical Illness Group 6 will cease to apply.
If the insured is diagnosed with any of the covered major illness, minor illness, early stage critical illness and / or severe child disease, we will pay:
The claims payment advanced for any covered illness under this policy cannot exceed 100% of the Initial Sum Assured (excluding any Terminal Bonus). However, multiple claims payments for covered illnesses may be made under the policy, subject to maximum limits which are applied according to the Critical Illness Group to which covered illness belong. Any advance claims payment(s) made will reduce the Current Sum Assured of the basic policy. The premium, guaranteed cash value, any future Annual Dividends and any future Terminal Bonus will also be reduced accordingly. Once advance claims payments for covered illnesses reaches 100% of the Initial Sum Assured, Annual Dividends and Terminal Bonus will no longer be credited and declared.
Once the advance claims payments made in total for benefits under the policy reach 100% of the Initial Sum Assured, the insured will remain covered under multiple illnesses protection before the insured reaches the age of 85 when a subsequent illness is diagnosed if:
Subsequent claims are subject to a waiting period of 1 year between any major illnesses, except that for subsequent claims between cancers, a waiting period of 3 years is required. There is no waiting period for subsequent early stage critical illnesses and subsequent severe child diseases.
Before the insured reaches the age of 85, the benefit for covered illnesses (as shown in the Critical Illnesses Benefit Schedule) will remain in effect until the benefits paid for illnesses in the corresponding group reaches the maximum group limit. After the age of 85, multiple illnesses protection will end and advance claims payments for illnesses suffered across any and all Critical Illness Groups will be capped at 100% of the Initial Sum Assured.
We will deduct all outstanding debt under your policy before making any claim payment.
The younger you are when your critical illness protection begins, the lower the premium and the longer the cover period you obtain. That is why parents usually buy insurance policies for their children. However, policies often fail to cover congenital diseases, which may remain undetected for years and could develop into a critical illness. Smart Elite Ultra is the first plan in the market to address this gap, providing your children with thorough cover for critical illnesses related to congenital diseases with symptoms which remain undetected at policy issue, and protecting your financial plans from any surprise discovery of a lifechanging hereditary trait, for added peace of mind.
It is common for parents to buy extra cover in payor insurance to safeguard the continuity of their children’s health protection. To save you the hassle, Smart Elite Ultra is the first in the market to provide this cover with no additional purchase and no health information of the payor required. Under this cover, if you pass away before the age of 75 and provided that the policy has been in force for 2 years or more at the time of your death, the insured child will continue to enjoy cover under the policy without having to pay the remaining premiums of the basic plan until the insured child reaches the age of 25. This premium waiver is available for policies issued to insured under age 18, provided that you are aged 18 to 50 at policy issue.
Certain common benign conditions, such as benign breast disorder or elevated prostate-specific antigen (PSA) level, may potentially increase the risk of cancer. In unfortunate cases where benign conditions turn malignant and the malignancies do develop into cancer, one can be left with a glaring gap in protection, with little means to cover medical expenses.
AIA is the first in the market to extend cover to those who have already developed these benign conditions (see the table in the next page). A Benign Extra Benefit equivalent to 20% of the Initial Sum Assured will be offered for any cancer in each organ with covered benign conditions right at policy issue, provided that the insured fulfils our underwriting requirements.
After a year from policy issue, if the benign condition of the organ is proven to be no worse off or to have shown improvement, we will further extend the cover to full cancer protection of up to a maximum of 300% of the Initial Sum Assured under Critical Illness Group 1 (Cancer) subject to the prevailing rules of the company. Even if full cover for cancer of that organ cannot be extended, the Benign Extra Benefit will remain applicable as long as critical illness benefit is still available under the policy. Once such full cancer protection is extended or the 20% of the Initial Sum Assured is paid, the Benign Extra Benefit for that organ will cease.
Provided no claim has been made for Benign Extra Benefit for cancer in an organ with covered benign conditions, we will provide a Benign Extra Benefit of 4% of the Initial Sum Assured for each of up to 2 Carcinomas-in-situ occurring in different organs with covered benign conditions and / or 1 Early Stage Malignancy occurring in each organ with covered benign conditions, and, subject to the prevailing rules of the company, may provide a cover extension to fully cover Carcinoma-in-situ and Early Stage Malignancy in that organ after one year from policy issue. The advance payment(s) of Benign Extra Benefit for Carcinoma-in-situ or Early Stage Malignancy will be deducted from any Benign Extra Benefit (i.e. 20% of the Initial Sum Assured) payable subsequently for cancer in the same organ.
Diabetes is one of the most common lifestyle diseases and can be a precursor to many critical illnesses, including kidney failure, blindness and loss of limbs. Smart Elite Ultra provides comprehensive protection for diabetes complications, from the early to late stages of the disease, subject to the maximum benefit of the corresponding Critical Illness Group:
Covered Early stage critical illness as a diabetes complication: Benefit
Covered Major Illnesses related to diabetes: Benefit
# Subject to a maximum of HK$400,000/US$50,000 per life including the payment made for Diabetic Retinopathy under diabetes complications benefit, critical illness benefit and coverage booster.
▼ Including a diabetes complication benefit of 20% advance of Initial Sum Assured which will be payable 1 time under each policy
Smart Elite Ultra comes with a Coverage Booster that offers extra cover at the start of the policy. It is an extra benefit to increase the benefit paid for 58 critical illnesses (including 57 major illnesses and 1 minor illness), 44 early stage critical illnesses, 13 severe child diseases or the death benefit, provided that any of these benefits are paid out during the first 10 or 15 years of the policy, depending on the age of the insured at policy issue (see the Covered Illnesses Benefit Schedule).
READ UPGRADED PROTECTION
Once claims for covered illnesses reach 100% of the Initial Sum Assured, the subsequent premiums of the basic policy will be waived. Add-on plans (if any) attached to the basic policy will remain in force and provide cover if their respective premiums continue to be paid.
Smart Elite Ultra offers guaranteed cash value and nonguaranteed Annual Dividends. Such dividends (if any) shall be credited to your policy at the end of each policy year to give you additional liquidity, so you can enjoy extra cash flow along with comprehensive cover. You may choose to receive the Annual Dividends in cash or use them to reduce any premium due. Otherwise, these sums shall accumulate in your policy, potentially earning interest.
Once the basic policy has been in force for 5 years, Smart Elite Ultra also declares a non-guaranteed Terminal Bonus (if any) to you at least once per year that may grow your wealth. You may receive the Terminal Bonus when:
Terminal Bonus is a non-cumulative, non-guaranteed bonus, the amount of which is valid until the next declaration. The amount in each declaration may be greater or less than the previous amount based on a number of factors, including but not limited to investment returns and general market volatility.
Payment of the Terminal Bonus is not guaranteed. We determine the amount based on actual experience and it may vary based on the above. In the case of policy surrender, it may be less compared to other situations.
Please note that after the advance claims payments made in total for benefits under the policy reaches 100% of the Initial Sum Assured, the policy will not provide any further Annual Dividends and Terminal Bonus.
With Smart Elite Ultra, you can choose from 3 premium payment terms and enjoy life insurance and critical illness protection throughout the lifetime of the insured.
View premium payment terms
For your convenience, we offer this policy in US dollars and HK dollars.
Critical Illness
This refers to a disease or condition that is life-threatening.
Participating Insurance Plan
With this product, in addition to providing protection to you and your love ones, your policy can share the divisible surplus (if any) from product groups determined by us.
Premium
This is the fee you pay us for your policy.
Surrender
When you cancel your insurance policy, we may pay you an amount (called the surrender value).
This is a participating insurance plan designed to be held long term. Your premiums will be invested in a variety of assets according to our investment strategy, with the cost of policy benefits and expenses deducted as appropriate from premiums or assets. Your policy can share the divisible surplus (if any) from related product groups determined by us. We aim to ensure a fair sharing of profits between policy owners and shareholders, and among different groups of policy owners.
Future investment performance is unpredictable. Through our smoothing process, we aim to deliver more stable Annual Dividend and Terminal Bonus payments by spreading out the gains and losses over a longer period of time. Stable Annual Dividend and Terminal Bonus payments will ease your financial planning.
We will review and determine the Annual Dividend and Terminal Bonus amounts to be payable to policy owners at least once per year. The actual Annual Dividends and Terminal Bonus declared may be different from those illustrated in any product information provided (e.g. benefit illustrations). If there are any changes in the actual Annual Dividends and Terminal Bonus against the illustration or in the projected future Annual Dividends and Terminal Bonus, such changes will be reflected in the policy anniversary statement.
A committee has been set up to provide independent advice on the determination of the Annual Dividend and Terminal Bonus amounts to the Board of the Company. The committee is comprised of members from different control functions or departments within the organisation both at AIA Group level as well as Hong Kong local level, such as office of the Chief Executive, legal, compliance, finance and risk management. Each member of the committee will exercise due care, diligence and skill in the performance of his or her duties as a member. The committee will utilise the knowledge, experience, and perspectives of each individual member to assist the Board in the discharge of its duty to make independent decision and to manage the risk of conflict of interests, in order to ensure fair treatment between policy owners and shareholders, and among different groups of policy owners. The actual Annual Dividends and Terminal Bonus, which are recommended by the Appointed Actuary, will be decided upon the deliberation of the committee and finally approved by the Board of Directors of the Company, including one or more Independent Non-Executive Directors, and with written declaration by the Chairman of the Board, an Independent Non-Executive Director and the Appointed Actuary on the management of fair treatment between policy owners and shareholders.
To determine the Annual Dividends and Terminal Bonus of the policy, we consider both past experiences and the future outlook for all the factors including, but not limited to, the following:
Investment returns: include interest earnings, dividends and any changes in the market value of the product’s backing assets. Depending on the asset allocation adopted for the product, investment returns could be affected by fluctuations in interest income (both interest earnings and the outlook for interest rates) and various market risks, including credit spread and default risk, fluctuations in equity prices, property prices and foreign exchange currency fluctuation of the backing asset against the policy currency.
Claims: include the cost of providing death benefits and other insured benefits under the product(s).
Surrenders: include policy surrenders, partial surrenders and policy lapses; and the corresponding impact on the investments backing the product(s).
Expenses: include both expenses directly related to the policy (e.g. commission, underwriting, issue and premium collection expenses) and indirect expenses allocated to the product group (e.g. general administrative costs).
Some participating products (if applicable) allow the policyholder to leave annual dividends, guaranteed and non-guaranteed cash payments, guaranteed and non-guaranteed incomes, guaranteed and non-guaranteed annuity payments with us, potentially earning interest at a non-guaranteed interest rate. To determine such interest rate, we consider the returns on the pool of assets in which the annual dividends, guaranteed and non-guaranteed cash payments, guaranteed and non-guaranteed incomes, guaranteed and non-guaranteed annuity payments are invested with reference to the past experience and future outlook. This pool of assets is segregated from other investments of the Company and may include bonds and other fixed income instruments. You have the right to request for historical accumulation interest rates before committing the purchase.
For dividend & bonus philosophy and dividend / bonus history, please visit our website at https://www.aia.com.hk/en/dividend-philosophy-history.html
Our investment philosophy is to deliver stable returns in line with the product’s investment objectives and AIA’s business and financial objectives.
Our investment policy aims to achieve the targeted long-term investment results and minimise volatility in investment returns over time. It also aims to control and diversify risk exposures, maintain adequate liquidity and manage the assets with respect to the liabilities.
Our current long-term target strategy is to allocate assets attributed to this product according to the target asset mix on the asset class below:
Bonds and other fixed income instruments: 55% - 75%
Growth assets: 25% - 45%
Our investment strategy is to actively manage the investment portfolio i.e.: adjust the asset mix in response to the external market conditions. The proportion of growth assets would be lower when interest rate level is low and would be even lower than the long-term target strategy so to protect the guaranteed liability and to minimise volatility in investment returns over time, and vice versa when interest rate is high.
The bonds and other fixed income instruments predominantly include government and corporate bonds, and are mainly invested in the geographic region of the United States and Asia-Pacific. Growth assets may include listed equity, equity mutual funds, physical real estate, real estate funds, private equity funds and private credit funds, which are mainly invested in the United States, Asia-Pacific and Europe. Returns of growth assets are generally more volatile than bonds and other fixed income instruments. Subject to our investment policy, material amount of derivatives may be utilised to manage our investment risk exposure and for matching between assets and liabilities.
Our currency strategy is to minimise currency mismatches. For bonds or other fixed income instruments, our current practice is to currency-match their bond purchases with the underlying policy denomination on best-efforts basis (e.g. US Dollar assets will be used to support US Dollar liabilities and HK Dollar assets will be used to support HK Dollar liabilities). Subject to market availability and opportunity, bonds may be invested in currency other than the underlying policy denomination and currency swap will be used to minimise the currency risks. Currently assets are mainly invested in US Dollar. Growth assets may be invested in currency other than the underlying policy denomination, and the currency exposure depends on the geographic location of the underlying investment where the selection is done according to our investment philosophy, investment policy and mandate.
We will pool the investment returns from other long term insurance products (excluding investment linked assurance schemes and pension schemes) together with this participating insurance plan for determining the actual investment and the return will subsequently be allocated with reference to the target asset mix of the respective participating products. Actual investments (e.g. geographical mix, currency mix) would depend on market opportunities at the time of purchase. Hence it may differ from the target asset mix.
The investment strategy may be subject to change depending on the market conditions and economic outlook. Should there be any material changes in the investment strategy, we will inform policy owners of the changes, with underlying reasons and impact to the policies.
If no non-forfeiture option has been elected, the premium will be covered by a loan taken out on the policy automatically. When the loan balance exceeds the sum of guaranteed cash value and accumulated Annual Dividends with interest (if any) of the basic plan, the policy will lapse and you will lose the cover. The surrender value of the policy will be used to repay the loan balance, and we will refund any remaining value.
Except for the death benefit and compassionate cash benefit, under this plan, we will not cover any of the following events or conditions that result from any of the following events:
The above list is for reference only. Please refer to the policy contract of this plan for the complete list and details of exclusions.
In order to provide you with continuous protection, we will review the premium of your plan from time to time within the premium payment term and adjust accordingly if necessary. During the review, we may consider factors including but not limited to the following:
We will give you a written notice of any revision 31 days before the end of policy year.
In case the insured reaches the age of 70 or above and makes any subsequent claim for prostate cancer resulting from the continuation of a previous prostate cancer for which a previous claim was made, the benefit will only be payable if the insured has received or is in the process of receiving the full course of cancer-directed surgery, radiotherapy, chemotherapy, targeted therapy or a combination of these treatments (excluding hormonal therapy) which is medically necessary during the intervening period between the diagnosis of the previous and subsequent prostate cancer.
“Medically necessary” means that the medical services, diagnosis and / or treatments are:
Experimental, screening, and preventive services or supplies are not considered medically necessary.
If you wish to make a claim, you must send us the appropriate forms and relevant proof. You can get the appropriate claim forms in www.aia.com.hk, from your financial planner, by calling the AIA Customer Hotline (852) 2232 8888 in Hong Kong, or by visiting any AIA Customer Service Centre. For detail claim procedures, please refer to the Claim Procedure section in the policy contract. If you wish to know more about claim related matter, you may visit “File A Claim” section under our company website www.aia.com.hk.
If the insured commits suicide within one year from the date on which the policy takes effect, our liability will be limited to the refund of premiums paid (without interest) less any outstanding debt.
Except for fraud or non-payment of premiums, we will not contest the validity of this policy after it has been in force during the lifetime of the insured for a continuous period of two years from the date on which the policy takes effect. This provision does not apply to any add-on plan providing accident, hospitalisation or disability benefits.
Like what you've read? This is just a summary of our product. If you want more information, please contact your financial planner for a financial needs analysis.